In the global pharmaceutical industry, there were 376 M&A deals announced in Q3 2023, worth a total value of $33.3bn, according to GlobalData’s Deals Database. The $7.3bn acquisition of Reata Pharmaceuticals by Biogen was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity decreased by 38% in Q3 2023 compared with the previous quarter’s total of $53.3bn and rose by 6% as compared to Q3 2022. Related deal volume decreased by 23% in Q3 2023 versus the previous quarter and was 1% higher than in Q3 2022.
Notably, healthcare-related deals accounted for a 30% share of the global pharmaceutical industry’s M&A activity in Q3 2023, up 21% over the previous quarter.
The top-ranked financial advisors supporting these M&A deals in Q3 2023 were Centerview Partners; Bank of America; Evercore with 17, 9, 9 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q3 2023 were Kirkland & Ellis; Goodwin Procter; Gibson, Dunn & Crutcher with 22, 21, 19 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.